



FACT SHEET

Below are key facts about the Eversense 365 CGM system. If you want to learn more or would like to speak to us about a media opportunity, then please get in touch with our press team at AscensiaComms@fticonsulting.com

Please note for important safety information, see <https://www.eversensed diabetes.com/safety-info>

<p>Diabetes Today</p>	<p>Diabetes is a significant global health challenge which often relies on self-management 24/7, 365-days a year.</p> <p>Technology has improved dramatically, providing people with better tools to help them manage their condition, reducing the burden and improving treatment outcomes.</p> <p>One of the biggest evolutions in diabetes technology is continuous glucose monitoring (CGM), which offers real-time glucose updates from a device attached to the body, often to a smartphone.</p> <p>However, many people with diabetes experience frustrations with traditional short-term CGMs, such as:</p> <ul style="list-style-type: none"> • CGMs stop working before the indicated 10-14 day wear time, wasting time and money • Unexpected disruptions from CGMs getting knocked off • Disruptive false alerts, including during the night • Skin irritation or discomfort from harsh adhesives <p>The American Diabetes Association recognizes that, while CGM technology is proven to help improve glucose control, it can add to the emotional burden of daily-self management¹.</p>
<p>Eversense 365 CGM System</p>	<p>One Year. One CGM.</p> <p>Eversense 365 is the world's first and only One Year CGM system.</p> <p>It is a One Year CGM system indicated for the management of type 1 and type 2 diabetes in adults aged 18 and over.</p> <p>Eversense offers people with diabetes a truly differentiated CGM experience.</p> <p>It helps people overcome common frustrations and interruptions experienced with traditional, short-term CGMs.</p> <p>Eversense 365 is the only CGM that provides one year of accurate monitoring with minimal interruptions, enabling confident decisions, long-term peace of mind, and enhanced quality of life with just one CGM.</p>

eversense 365

Continuous Glucose Monitoring System

	<p>The Eversense 365 CGM system consists of three main components: an implantable fluorescence-based glucose sensor, a removable Smart Transmitter*, and a Mobile App to display the glucose data.</p> <p>The tiny sensor rests comfortably under the skin for a full year, providing exceptional accuracy over one year, so that people can focus on managing their diabetes and not their CGM.</p> <p>Eversense has been found to reduce diabetes distressⁱⁱ and deliver significant improvements in glucose controlⁱⁱⁱ, reducing the CGM device burden and allowing people to feel more empowered in their diabetes self-management.</p>
<p>The Unique Benefits</p>	<p>Eversense 365 is the only ONE YEAR CGM, and it is designed to help minimize device frustrations so people can manage their diabetes – and their daily life.</p> <p>Longest lasting CGM: The only CGM that lasts for a year, while traditional 10-14 day CGMs tend to fail early.^{iv,v,vi}</p> <p>No more wasted CGMs: The removable* smart transmitter can be taken off when needed. If the transmitter gets knocked off, simply put it back on without wasting a CGM.</p> <p>Trusted alerts: Eversense 365 has exceptional accuracy for one year, with almost no compression lows and false alerts when sleeping^{vii}</p> <p>Maximum comfort: The gentle, silicone-based adhesive are changed daily and cause almost no skin reactions^{viii}</p>

* There is no glucose data generated when the transmitter is removed.

ⁱ American Diabetes Association. Continuous Glucose Monitoring and Diabetes Distress. American Diabetes Association. Published March 2024. Accessed August 30, 2024. <https://professional.diabetes.org/sites/dpro/files/2024-03/CGMandDiabetesDistress.pdf>

ⁱⁱ An 8.5% reduction in total diabetes distress over two years of Eversense CGM system use (n=273). Source: Tweden KS, et. al. Data presented during ATTD 2024. Patient reported outcomes of the Eversense CGM system in the U.S. Post approval setting.

ⁱⁱⁱ Tweden KS, et al. (2023) Implantable CGM Use Improves Glycemic Control in CGM Naive Patients. Interventions Obes Diabetes. 6(1). IOD. 000635.2023.Compared to end of SMBG phase.

^{iv} Senseonics. (2024) Eversense 365 CGM System User Guide.

^v Abbott. (2024) Freestyle Libre 3 User Guide ART49385-001 Rev. A 04/24

^{vi} Dexcom (2024) G7 User Guide AW00078-10 Rev 003 MT-00078-10

^{vii} Christiansen MP, Klaff LJ, Brazg R, et al. (2018) A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. *Diabetes Technol Ther.* 20(3):197-206. doi:10.1089/dia.2017.0142

^{viii} Deiss, D. et al. (2020). Real-world safety of an implantable continuous glucose sensor over multiple cycles of use: A post-market registry study. *Diabetes Technology & Therapeutics*, 22(1), 48–52.